Workflow
Board renewal
icon
Search documents
WiseTech (ASX:WTC) share price soars 6% after leadership appointment
Rask Media· 2025-11-27 03:57
Core Insights - WiseTech Global Ltd's share price increased by 6% following the announcement of a new independent director appointment [1] - The company aims to enhance its board with the right mix of independent directors to support future growth [2][4] Group 1: Leadership Changes - Raelene Murphy has been appointed as an independent non-executive director, effective January 1, 2026, and will join the audit and risk committee [2] - Following her appointment, WiseTech will have five independent directors and two executive directors, with plans to add at least one more independent director in the future [3] Group 2: Director's Background - Ms. Murphy has extensive experience as a non-executive director and audit committee chair for ASX-listed companies, including Bega Cheese Ltd and Tabcorp Holdings Limited [5] - She has over 35 years of executive experience in strategic, financial, and operational leadership, previously serving as managing director at KordaMentha and CEO of the Delta Group [6] Group 3: Market Position and Potential - WiseTech is regarded as one of the top companies on the ASX, despite a 40% drop in share price since August [7] - The company has strong potential for earnings growth, which is essential for increasing its share price [7][8]
Calian Group Announces Governance Changes to Support Strategic Operations Following Agreement with Plantro Ltd.
Globenewswire· 2025-11-11 12:00
-  Enters co-operation agreement with Plantro Ltd.-  Accelerates ongoing board renewal process- Forms special committee to oversee the execution of actions related to non-core assets, to include participation by special advisor recommended by Plantro OTTAWA, Ontario, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Calian® Group Ltd. (TSX:CGY) (“Calian” or the “Company”), a mission-critical solutions company focused on defence, space, healthcare and other strategic critical infrastructure sectors, announces that it is acc ...
Calian Group Announces Governance Changes to Support Strategic Operations Following Agreement with Plantro Ltd.
Globenewswire· 2025-11-11 12:00
Core Insights - Calian Group Ltd. is accelerating its board renewal process and has formed a special committee to oversee actions related to non-core assets, following a cooperation agreement with Plantro Ltd., a significant shareholder [1][6] Board Renewal Process - The board renewal process includes the retirement of George Weber and Kevin Ford, with Jo-Anne Poirier also not seeking re-election [3] - New board members Lisa Greatrix, Josh Blair, and Eric Demirian were added earlier this year, and incoming CEO Patrick Houston will join the board on January 1, 2026 [4] Focus on Non-Core Assets - Calian has identified certain non-core assets for divestiture as part of a portfolio review, and a temporary committee of independent directors has been formed to oversee these initiatives [5] - The committee includes Josh Blair, Eric Demirian, and Val Sorbie, with Stephen Halperin acting as a special advisor [5] Cooperation Agreement with Plantro - The cooperation agreement with Plantro includes commitments to accelerate board renewal and establish the independent committee, along with standstill and non-disparagement provisions effective until November 1, 2026 [6] - This agreement reflects Calian's commitment to constructive engagement with shareholders [6] Strategic Opportunities - The board and management team are focused on executing a refined strategy to capitalize on significant opportunities in the defense and related sectors, driven by anticipated increases in defense spending [2]
Novo Nordisk chair and independent directors to exit in strategy dispute
Yahoo Finance· 2025-10-21 12:58
Group 1 - The chair of Novo Nordisk and six independent board members will resign due to a strategic dispute with the controlling shareholder, the Novo Nordisk Foundation [1][3] - The Foundation plans to propose Lars Rebien Sorensen as the temporary chairman for a period of two to three years [2] - The company has undergone significant leadership changes, including the ousting of CEO Lars Fruergaard Jorgensen and the initiation of a restructuring plan involving 9,000 job cuts [2] Group 2 - The board renewal is deemed necessary by the Foundation to adapt to the rapidly changing environment in the obesity drug market [3] - There was a lack of consensus between the board and the Foundation regarding the extent of the board renewal, with the board favoring selective additions and the Foundation advocating for a more comprehensive reconfiguration [4] - Helge Lund has served as chair of Novo's board since 2018 [4]